NCT05296278 2024-01-10
Efficacy and Biomarker Explanation of IBI-323 + Bevacizumab Plus Platinum Based Chemotherapy on ALK-Rearranged NSCLC
Hunan Province Tumor Hospital
Phase 2 Unknown
Hunan Province Tumor Hospital
Jiangsu Cancer Institute & Hospital
Tang-Du Hospital
Fudan University
Sichuan Cancer Hospital and Research Institute
Sun Yat-sen University
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Peking Union Medical College Hospital
Tianjin Medical University Cancer Institute and Hospital
Fudan University
Qilu Hospital of Shandong University